Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02586207
Title Pembrolizumab in Combination With CRT for LA-SCCHN
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Sanford Health

oral squamous cell carcinoma

head and neck squamous cell carcinoma

laryngeal squamous cell carcinoma

oropharynx cancer

hypopharynx cancer


Cisplatin + Pembrolizumab

Age Groups: adult
Covered Countries USA

No variant requirements are available.